Crinetics Pharmaceuticals (CRNX) Short-term Investments (2018 - 2026)

Crinetics Pharmaceuticals' Short-term Investments history runs 9 years deep, the most recent figure standing at $1.2 billion for Q1 2026.

• On a quarterly basis, Short-term Investments changed 0.22% year-over-year to $1.2 billion in Q1 2026; TTM through Mar 2026 was $1.2 billion, a 0.22% change from a year earlier, with the FY2025 full-year figure at $926.4 million, down 14.98% from the prior year.
• Short-term Investments climbed to $1.2 billion in Q1 2026 per CRNX's latest filing, from $926.4 million in the prior quarter.
• Across five years, Short-term Investments topped out at $1.2 billion in Q1 2025 and bottomed at $500000.0 in Q2 2025.
• The 5-year median for Short-term Investments is $411.9 million (2023), against an average of $502.3 million.
• Across the five-year window, Short-term Investments surged 1285.35% in 2022 and tumbled 99.91% in 2025, its largest moves.
• Year by year, Short-term Investments stood at $301.8 million in 2022, then soared by 66.91% to $503.7 million in 2023, then surged by 116.32% to $1.1 billion in 2024, then slipped by 14.98% to $926.4 million in 2025, then grew by 27.05% to $1.2 billion in 2026.
• Per Business Quant, the three latest CRNX Short-term Investments figures stand at $1.2 billion (Q1 2026), $926.4 million (Q4 2025), and $500000.0 (Q3 2025).